Prostate cancer gene therapy (Mayne)

N/A

Report date: 2024/09/10 15:25:11

Base Information

Drug NameProstate cancer gene therapy (Mayne)
Drug Alias NameFP-253
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionPurine nucleoside phosphorylase stimulants
TargetsPurine nucleoside phosphorylase
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSymbion Health
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSymbion Health
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A